EMA — authorised 9 November 2016
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Status: approved
🇪🇺 Lartruvo in European Union
EMA authorised Lartruvo on 9 November 2016
Marketing authorisations
EMA — authorised 9 November 2016
- Application: EMEA/H/C/004216
- Marketing authorisation holder: Eli Lilly Nederland B.V.
- Local brand name: Lartruvo
- Indication: Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).
- Pathway: accelerated assessment, conditional
- Status: withdrawn
Lartruvo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in European Union
Frequently asked questions
Is Lartruvo approved in European Union?
Yes. EMA authorised it on 9 November 2016; EMA authorised it on 9 November 2016.
Who is the marketing authorisation holder for Lartruvo in European Union?
Eli Lilly Nederland B.V. holds the EU marketing authorisation.